Microsoft says its new health AI beat doctors in accurate diagnoses by a mile
Microsoft said its medical AI diagnosed cases four times as accurately as human doctors.
The AI system also solved cases "more cost-effectively" than its human counterparts, Microsoft said.
The study comes as AI's growing role in healthcare raises questions about its place in medicine.
Microsoft said its medical AI system diagnosed cases more accurately than human doctors by a wide margin.
In a blog post published on Monday, the tech giant said its AI system, the Microsoft AI Diagnostic Orchestrator, diagnosed cases four times as accurately as a group of experienced physicians in a test.
Microsoft's study comes as AI tools rapidly make their way into hospitals and clinics, raising questions about how much of medicine can or should be automated and what role doctors will play as diagnostic AI systems get more capable.
The experiment involved 304 case studies sourced from the New England Journal of Medicine. Both the AI and physicians had to solve these cases step by step, just like they would in a real clinic: ordering tests, asking questions, and narrowing down possibilities.
The AI system was paired with large language models from tech companies like OpenAI, Meta, Anthropic, and Google. When coupled with OpenAI's o3, the AI diagnostic system correctly solved 85.5% of the cases, Microsoft said.
By contrast, 21 practicing physicians from the US and UK — each with five to 20 years of experience — averaged 20% accuracy across the completed cases, the company added. In the study, the doctors did not have access to resources they might typically tap for diagnostics, including coworkers, books, and AI.
The AI system also solved cases "more cost-effectively" than its human counterparts, Microsoft said.
"Our findings also suggest that AI reduce unnecessary healthcare costs. US health spending is nearing 20% of US GDP, with up to 25% of that estimated to be wasted," it added.
"We're taking a big step towards medical superintelligence," said Mustafa Suleyman, the CEO of Microsoft's AI division, in a post on X.
He added that the cases used in the study are "some of the toughest and most diagnostically complex" a physician can face.
Suleyman previously led AI efforts at Google.
Microsoft did not respond to a request for comment from Business Insider.
Microsoft said in the blog post that AI "represents a complement to doctors and other health professionals."
"While this technology is advancing rapidly, their clinical roles are much broader than simply making a diagnosis. They need to navigate ambiguity and build trust with patients and their families in a way that AI isn't set up to do," Microsoft said.
"Clinical roles will, we believe, evolve with AI," it added.
Tech leaders like Microsoft cofounder Bill Gates have said that AI could help solve the long-standing shortage of doctors.
"AI will come in and provide medical IQ, and there won't be a shortage," he said on an episode of the "People by WTF" podcast published in April.
But doctors have told BI that AI can't and shouldn't replace clinicians just yet.
AI can't replicate physicians' presence, empathy, and nuanced judgment in uncertain or complex conditions, said Dr. Shravan Verma, the CEO of a Singapore-based health tech startup.
Chatbots and AI tools can handle the first mile of care, but they must escalate to qualified professionals when needed, he told BI last month.
Do you have a story to share about AI in healthcare? Contact this reporter at cmlee@insider.com.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Q'Apel Medical Appoints Stewart Strong as President and Chief Executive Officer
Innovation-focused leader with a proven track record of driving outsized growth and profitability to lead the company's next chapter FREMONT, Calif., July 1, 2025 /PRNewswire/ -- Q'Apel Medical (Q'Apel), a private medical device company focused on revolutionizing neurovascular interventions, today announced the appointment of veteran medtech executive, Stewart Strong, as President and Chief Executive Officer. In this role, Strong will lead Q'Apel's team as it looks to expand its market presence, deliver clinical value for physicians and patients, and advance the company's pipeline of innovation. "Stew is the right person at the right time to lead Q'Apel through our next phase of growth," remarked R. King Nelson, Q'Apel's Chairman of the Board. "He brings a passion for building and leading high-performing global teams and for developing commercial strategies to drive sustainable growth, which will serve him well as Q'Apel looks to accelerate our commercial performance in the U.S. and ramp up our global presence." With over 25 years of leadership experience in the medical device sector, Mr. Strong brings a wealth of experience in creating high-performing global teams, both in large, publicly traded enterprises and privately backed organizations. He comes to Q'Apel from Haemonetics, where he served as Global President of the Hospital Business Unit. In this role, Strong established a world-class global commercial organization, launched innovative technologies, and successfully executed corporate strategies, collectively generating a threefold increase in revenue during his tenure. Previously, Strong served as President of the Teleflex Interventional franchise and was responsible for expanding the company's penetration in the interventional cardiology and radiology spaces. Additionally, Mr. Strong held executive leadership roles at Vidacare Inc. (acquired by Teleflex in 2013) and at AtriCure, Inc. He has also served on the Board of Directors of Vivasure Medical and Obvius Robotics. "I am honored to assume this position and am excited to get started. Q'Apel is a leader in the neurovascular space, recognized for driving innovation and its customer-centricity," commented Strong. "I look forward to working with the Board of Directors, the executive leadership, and the global Q'Apel team to drive growth, shape our future, and to realize our full potential." About Q'Apel Medical: Q'Apel Medical is revolutionizing neurovascular interventions. Inspired by the evolving needs of our customers, our novel approach allows us to solve clinical challenges where others fall short. We are up for the task, the more complex the better. Our team thrives on creating high quality uniquely engineered products, designed in partnership with neurovascular specialists, that address what is needed right now, yet with the versatility to focus on what is coming next. For more information, visit Media Contact:Charlene HerndonSPRIG Consultingcharlene@ View original content to download multimedia: SOURCE Q'Apel Medical Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Woman Reveals How a Lip Flip Impacted Her Sex Life as She Details Procedure's Shocking Side Effects (Exclusive)
In May, aesthetic nurse injector Brooke Carrero posted a TikTok video detailing the side effects of a lip flip, which involves injecting neurotoxin to the area above the upper lip for a plumper, fuller effect Carrero used her video as a PSA to patients interested in the enhancement, which she said affected how she drank water and pronounced certain words Speaking with PEOPLE exclusively, Carrero reveals how the effects, which lasted around 48 hours, also impacted her sex life: "My skill set probably went from a 10 down to a six"Brooke Carrero, a registered nurse trained in aesthetic injections, is getting loose lipped about one of the most common cosmetic procedures. She posted a viral TikTok video in May revealing some of the side effects caused by the cosmetic enhancement, which involves injecting neurotoxin, a substance used by injection brands like Botox, to relax the surrounding areas of the upper lip to make them flip upward, giving them a fuller appearance. Right now, Botox is not FDA-approved to treat the lips, unlike fillers, which is why it is considered "off-label" for lip flips as opposed to its relation to treating crow's feet and frown and forehead lines. Though, that doesn't mean lip flips are entirely off the market, causing curiosity around the procedure to grow; a report published by the National Library of Medicine discovered a 33% monthly increase in the search volume for lip flips from 2014-2024. Carrero, who is based in Philadelphia and practices under Becker Plastic Surgery and Dr. Kirk Lozada, shocked viewers when she revealed how the treatment made it more difficult to do ordinary activities, such as drinking out of a straw, brushing her teeth, applying lip gloss and even pronouncing words with Bs and Ps. But the most surprising admission from Carrero, 34, was how it impacted her sex life, a topic she was cheeky about in her TikTok video ("You can't blow out a candle, which means you can't blow anything. Use your imagination there," she joked), but open about in her interview with PEOPLE. "My skill set probably went from a 10 down to a six," she says. But, "I feel like I've gotten used to the way that my mouth kind of moves," she says, adding that her husband is so used to her experimenting with different treatments that he "laughs at me with my side effects." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Luckily, Carrero notes that side effects usually last one to two days, while the lip flip itself can last up to three to four weeks. A playing factor is the number of units of neurotoxin injected into the patient. For her clients, Carrero commonly uses around four to six units (each of which costs around $14 at Carrero's practice), which the American Board of Facial Cosmetic Surgery also suggests. Yet currently, Carrero has 16 units injected around her mouth — and yes, she did them herself. "I am somebody that needs to try everything and expose myself to complications so I'm able to relate to my patients," she tells PEOPLE on why she goes to extremes for research purposes. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! After her video went viral, Carrero received tons of comments from people thanking her for cluing them in on the temporary hinderances of a lip flip. "No one tells you this!" one person wrote, while another person agreed, sharing that they wish they knew this before getting the treatment. At the end of the day, Carrero approaches the conversation around cosmetic treatments with an open mind. "There's nothing that you need to have done, like nobody needs a lip flip and nobody needs cosmetic procedures, but it's a matter of want. If it makes you feel good, don't let anyone make you feel otherwise." Read the original article on People
Yahoo
31 minutes ago
- Yahoo
Michael Saylor's Strategy to Join Wall Street Elite With $14 Billion Windfall
(Bloomberg) — Michael Saylor's Strategy (MSTR) is likely to register an unrealized gain of about $14 billion in the second quarter, putting the once floundering enterprise software maker turned leveraged Bitcoin proxy among the select ranks of corporate titans such as Inc (AMZN). and JPMorgan Chase & Co. (JPM) Struggling Downtowns Are Looking to Lure New Crowds Philadelphia Transit System Votes to Cut Service by 45%, Hike Fares Squeezed by Crowds, the Roads of Central Park Are Being Reimagined Sprawl Is Still Not the Answer Unlike the ten or so US multinationals whose operating profits are expected to exceed $10 billion last quarter by generating billions of dollars in sales, the former MicroStrategy Inc. can attribute the eye-popping results to a rebound in the price of Bitcoin (BTC-USD) and a fairly recent accounting change when it comes to valuing its massive holdings of the cryptocurrency. Strategy is forecast to post only about $112.8 million in second-quarter revenue from the software business, according to analysts surveyed by Bloomberg News. The likely record profit for the three months ended June 30 follows a barrage of criticism from naysayers such as Jim Chanos. The renowned short-seller has recommended an arbitrage trade to short the shares of Strategy and buy Bitcoin, betting the large premium the stock commands over the value of its token holdings will shrink. The call has sparked a war of words that has captivated Wall Street, with Chanos calling Saylor's model to value the crypto-treasury firm 'financial gibberish' while Saylor argued that Chanos just does not understand it. 'Saylor definitely has a right to feel vindicated,' said Mark Palmer, an analyst at Benchmark Capital, who has maintained a 'buy' rating on Strategy since February 2024. 'He's had people criticizing him for more than four years now and his company has outperformed all other stocks and even the S&P by a long mile.' Strategy's shares have soared over 3,300% since Saylor began buying Bitcoin in the middle of 2020 as a hedge against inflation. Bitcoin is up around 1,000% during the same period, while the S&P 500 has increased around 115%. The stock rose 40% in the second quarter as the S&P climbed 11%. In the first quarter, Strategy adopted an accounting change that requires valuing the firm's now roughly $64 billion in Bitcoin at market prices. Strategy and fellow corporate buyers of Bitcoin are now recognizing the unrealized changes that often produce big swings in earnings. Strategy posted a record $4.2 billion loss the first quarter, which saw Bitcoin slump 12%. Prior to the accounting change, Strategy had been classifying its Bitcoin holdings similar to intangible assets like patents or trademarks. That designation forced Strategy to permanently mark down the value of its holdings when the price of Bitcoin dropped below the previous carrying value. Gains could only be recognized when tokens were sold. The company held 528,185 Bitcoin at the beginning of the quarter, worth over $43.5 billion when the tokens traded for about $82,444.71 each on March 31. The 30% appreciation in Bitcoin increased the market value of those holdings by over $13 billion alone, and the dozen weekly purchases since have tacked on over $600 million more to the unrealized gains, according to Bloomberg News calculations. Strategy is expected to release second-quarter results in August. A company representative didn't reply to a request for comment. Even though the change in accounting was widely known, the first-quarter loss has triggered several class-action lawsuits alleging Strategy executives made untrue and misleading statements that resulted in harm to shareholders. Strategy said it intended to 'vigorously defend against these claims' in a recent filing with the US Securities and Exchange Commission. Over the last five years, Strategy co-founder and Chairman Saylor has become a phenomenon on both Wall Street and in the crypto industry by turning his slowly-weathering business intelligence software company into the first and largest leveraged Bitcoin proxy in the world. 'I think what you're just seeing is the understanding of the value of owning Bitcoin on your balance sheet against the macro backward drop of inflation globally and the need to find a suitable vehicle to store your wealth,' said Ravi Doshi, a trader at FalconX. Funding of the buying binge has evolved into an elaborate combination of common stock and debt sales that has progressed to convertible offerings, and most recently, preferred share sales. Hedge funds have been driving demand for the convertible debt, as they seek out the company for trades that incorporate buying the bonds and selling the shares short, essentially betting on the underlying stock's volatility. Saylor's Bitcoin accumulation tactic has inspired dozens of copycats looking to emulate his success. Other companies are also altering the playbook to use other crypto tokens — Sharplink Gaming Inc., for example, is accumulating Ether, the second-largest cryptocurrency, while Upexi Inc. recently raised $100 million to buy the Solana token. BitMine Immersion Technologies Inc. announced a $250 million private placement to fund an Ether treasury on Monday. 'It remains to be seen whether these companies would be successful or not,' Palmer said. America's Top Consumer-Sentiment Economist Is Worried How to Steal a House SNAP Cuts in Big Tax Bill Will Hit a Lot of Trump Voters Too China's Homegrown Jewelry Superstar Pistachios Are Everywhere Right Now, Not Just in Dubai Chocolate ©2025 Bloomberg L.P. By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data